These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 7568327)

  • 21. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
    Glick SD; Maisonneuve IM; Szumlinski KK
    Ann N Y Acad Sci; 2000 Sep; 914():369-86. PubMed ID: 11085336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.
    Noller GE; Frampton CM; Yazar-Klosinski B
    Am J Drug Alcohol Abuse; 2018; 44(1):37-46. PubMed ID: 28402682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors.
    Leal MB; Michelin K; Souza DO; Elisabetsky E
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Aug; 27(5):781-5. PubMed ID: 12921910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.
    Brown TK; Alper K
    Am J Drug Alcohol Abuse; 2018; 44(1):24-36. PubMed ID: 28541119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies.
    Ross S
    Psychiatr Clin North Am; 2012 Jun; 35(2):357-74. PubMed ID: 22640760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Facilitation of memory retrieval by the "anti-addictive" alkaloid, ibogaine.
    Popik P
    Life Sci; 1996; 59(24):PL379-85. PubMed ID: 8950313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of antiaddictive actions of ibogaine.
    Glick SD; Maisonneuve IS
    Ann N Y Acad Sci; 1998 May; 844():214-26. PubMed ID: 9668680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neurochemical basis of ultra rapid opioid detoxication].
    Golovko AI; Leont'eva LV; Golovko SI; Zefirov SIu; Konoplin DA; Romanenko OP
    Vopr Med Khim; 2002; 48(2):154-73. PubMed ID: 12189623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synaptically-silent immature neurons show gaba and glutamate receptor-mediated currents in adult rat dentate gyrus.
    Ambrogini P; Minelli A; Lattanzi D; Ciuffoli S; Fanelli M; Cuppini R
    Arch Ital Biol; 2006 May; 144(2):115-26. PubMed ID: 16642790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of the effects of rewarding drugs by ibogaine.
    Parker LA; Siegel S
    Alkaloids Chem Biol; 2001; 56():211-25. PubMed ID: 11705109
    [No Abstract]   [Full Text] [Related]  

  • 31. GABA systems, benzodiazepines, and substance dependence.
    Malcolm RJ
    J Clin Psychiatry; 2003; 64 Suppl 3():36-40. PubMed ID: 12662132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine.
    O'Hearn E; Molliver ME
    Neuroscience; 2004; 127(2):373-83. PubMed ID: 15262328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fatalities temporally associated with the ingestion of ibogaine.
    Alper KR; Stajić M; Gill JR
    J Forensic Sci; 2012 Mar; 57(2):398-412. PubMed ID: 22268458
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating drug dependence with the aid of ibogaine: a retrospective study.
    Schenberg EE; de Castro Comis MA; Chaves BR; da Silveira DX
    J Psychopharmacol; 2014 Nov; 28(11):993-1000. PubMed ID: 25271214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies.
    Deecher DC; Teitler M; Soderlund DM; Bornmann WG; Kuehne ME; Glick SD
    Brain Res; 1992 Feb; 571(2):242-7. PubMed ID: 1377086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neurotrophic mechanisms of psychedelic therapy].
    Corne R; Mongeau R
    Biol Aujourdhui; 2019; 213(3-4):121-129. PubMed ID: 31829932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.
    Corkery JM
    Prog Brain Res; 2018; 242():217-257. PubMed ID: 30471681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Observations on treatment with ibogaine.
    Luciano D
    Am J Addict; 1998; 7(1):89-90. PubMed ID: 9522011
    [No Abstract]   [Full Text] [Related]  

  • 39. Medication development of ibogaine as a pharmacotherapy for drug dependence.
    Mash DC; Kovera CA; Buck BE; Norenberg MD; Shapshak P; Hearn WL; Sanchez-Ramos J
    Ann N Y Acad Sci; 1998 May; 844():274-92. PubMed ID: 9668685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue distribution of ibogaine after intraperitoneal and subcutaneous administration.
    Hough LB; Pearl SM; Glick SD
    Life Sci; 1996; 58(7):PL119-22. PubMed ID: 8632705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.